Special Issue

Proteometabolomics in Cancer

Message from the Guest Editors

The application of 'omics' technologies, coupled with advanced statistical approaches, is increasingly being utilized to reveal molecular drivers of tumorigenesis and to derive novel treatment strategies and biomarkers. While 'omics' approaches have largely been advanced in the areas of genomics and transcriptomics, there is considerable interest and merit in exploring proteomics and metabolomics data, as these offer detailed characterization of the functional molecular machinery and derived biochemical outputs that ultimately affect oncogenesis and shape the tumor microenvironment as well as tumor–host interaction. Using proteomics, metabolomics, or integrated proteomics and metabolomics approaches in the context of cancer thus has high relevance to the identification of next-generation treatment modalities that target cancer cell dependencies as well as to biomarkers. This Special Issue focuses on the application of proteomics, metabolomics, and integrated proteomics and metabolomics in cancer, with an emphasis on cancer biology, the tumor microenvironment and modulation of the tumor immunophenotype, biomarkers, and novel therapeutic strategies

Guest Editors

Prof. Dr. Samir M. Hanash

Department of Clinical Cancer Prevention, Division of Cancer Prevention and Population Sciences, University of Texas MD Anderson Cancer Center, Houston, TX, USA

Dr. Johannes Fahrmann

Department of Clinical Cancer Prevention, Division of Cancer Prevention and Population Sciences, University of Texas MD Anderson Cancer Center, Houston, TX, USA

Deadline for manuscript submissions

30 August 2026

About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:
free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:
indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:
JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)